Contrast agent firms Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced this month an expansion of their existing agreement to research and develop MR imaging technologies. Epix and Mallinckrodt will both fund research in
Contrast agent firms Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced this month an expansion of their existing agreement to research and develop MR imaging technologies. Epix and Mallinckrodt will both fund research in intravascular MRI contrast agents, and they will pursue additional applications for AngioMark, Epixs imaging agent, such as identifying peripheral vascular disease, coronary artery disease, and breast cancer. AngioMark has completed phase II clinical trials for peripheral vascular use, and is in phase II trials for the other two indications. Epix and Mallinckrodt would also like to research the use of AngioMark for macro- and micro-vessel imaging.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.